KYTXKyverna Therapeutics, Inc.
$6.18+14% 1Y
$6.18
$6.1552 weeks$11.25
KYTX as reported
- Net income
- −$153M
Net income · −3.8% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$154M
Free cash flow · trailing twelve months to Q4 2025
- EPS
- −$2.93
EPS · −20% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$153M | −3.8% | Q2 2026 |
| EPS | −$2.93 | −20% | Q2 2026 |
| ROE | −87% | n/a | Q2 2026 |
| ROA | −68% | n/a | Q2 2026 |
| Free cash flow | −$154M | n/a | Q4 2025 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Kyverna Therapeutics, Inc. (KYTX) · Net incomeNet incomeKyverna Therapeutics, Inc. (KYTX)
Biotechnology
The closest names by size in the same industry